Deleterious germ-line mutations in BRCA1 (breast cancer 1, early onset; MIM 113705) confer a high risk of breast and ovarian cancer [B(O)C].
3 BRCA1 genetic testing has revealed a large number of sequence variants, but only frameshifts and premature stop codons are generally assumed to be pathogenic without further analysis (1 ) . Therefore, a growing number of variants are being detected that cannot be readily distinguished as either disease-causing or neutral. In the Breast Cancer Information Core (BIC) database, 691 such variants were listed as of October 2009 (2 ) . These so-called unclassified variants (UVs) pose serious problems in genetic counseling, ranging from the impossibility of accurate risk assessment to psychological aspects (3 ) .
Several approaches have been proposed to reclassify BRCA1 UVs into either disease-causing or neutral variants (1 ) . Often, testing the effect of UVs on RNA splicing becomes essential to assess their pathogenicity. For instance, exon skipping or the activation of a cryptic splice site (leading to the deletion/insertion of exonic/intronic sequences) provides strong evidence that the variant is pathogenic. On the contrary, correct RNA processing suggests that the variant is neutral (4 -14 ) . Surprisingly, the existence of naturally occurring BRCA1 splicing isoforms (15 ) is mostly overlooked when the role of BRCA1 variants on splicing is tested.
We report the identification and characterization of allele-specific splicing (ASS) linked to the nonpathogenic BRCA1 variant c.591CϾT. Our study illustrates the importance of taking into consideration naturally occurring BRCA1 splicing isoforms when assessing the pathogenicity of BRCA1 UVs affecting splicing.
Materials and Methods

PARTICIPANT RECRUITMENT
Index cases from 685 B(O)C families were identified by the Familial Cancer Clinic of our hospital during the period 1998 -2009. B(O)C families fulfilled at least one of the following inclusion criteria: 3 breast and/or ovarian cancer cases diagnosed in 2 generations of the same parental branch, 2 breast and/or ovarian cancer cases diagnosed at Ͻ50 years of age in the same parental branch, or 1 breast cancer case diagnosed at Ͻ35 years of age.
We recruited 450 healthy female blood donors visiting the blood bank of our hospital during the period 2002-2009. None of the blood donors reported any history of cancer in first-degree relatives.
Sporadic breast cancer cases (n ϭ 326) were identified by the Oncology Department of our hospital during the period 2002-2008. All female breast cancer cases classified as sporadic were eligible for the present study. We classified breast cancer cases as sporadic if no first-degree relatives with breast cancer had been reported.
All participants provided written informed consent. The institutional ethics committee approved the study.
BRCA1 GENOTYPING
Genomic DNA was extracted from peripheral blood lymphocytes in a fully automated nucleic acidpurification workstation (MagNA Pure Compact System; Roche Diagnostics). MagNA Pure Compact Nucleic Acid Isolation Kit I-Large Volume was used according to the manufacturer's protocol. Index cases from B(O)C families were scanned for the presence of BRCA1 germ-line mutations by denaturing gradient gel electrophoresis and sequencing, as previously described (16 ) . We used denaturing gradient gel electrophoresis to genotype c.591CϾT (p.197ϭ), c.5123CϾA (p.A1708E), and 14 BRCA1 tagging single-nucleotide polymorphisms (SNPs) in sporadic breast cancer cases and in healthy controls. BRCA1 tagging SNPs have been described previously (17 ) . Human Genome Variation Society guidelines (http://www.hgvs.org) were used for BRCA1 mutation nomenclature.
IN SILICO SPLICING ANALYSIS
The following splice-site analysis tools were used: (a) Berkeley Drosophila Genome Project (BDGP) (http:// www.fruitfly.org/seq_tools/splice.html); (b) NetGene2 (NG2) (http://www.cbs.dtu.dk/services/NetGene2); and (c) Human Splicing Finder (HSF) (http://www. umd.be/HSF/).
Human default parameter settings were used in all analyses. BDGP, NG2, and HSF matrices were used to analyze the effect of the c.591CϾT variant on donor site efficiency. In addition, the following HSF matrices were used to analyze the effect of the c.591CϾT variant on the following putative splicing regulatory sequences: HSF integrated matrices for serine/arginine-rich proteins (SRp40, SC35, SF2/ASF, SF2/ASF IgM/ BRCA1, and SRp55), exonic splicing enhancer (ESE) motifs from HSF (ESE-HSFs), RESCUE ESE hexamers (RESCUE-ESE), putative 8-mer ESEs (PESEs) and putative 8-mer exonic splicing silencers (PESSs), exonidentity and intron-identity elements (EIEs and IIEs), heterogeneous nuclear ribonucleoprotein-binding motifs, and Fas exonic splicing silencers. A comprehensive description of these splicing regulatory elements can be found elsewhere (18 ) .
The analysis was performed with a 400-bp sequence centered on the c.591CϾT variant. In accordance with other studies (19 ) , a scoring decrease Ͼ10% was considered predictive of splicing alterations.
cDNA SYNTHESIS
We analyzed 7 c.591CϾT carriers (3 index cases, 2 relatives, and 2 healthy controls) and 10 noncarriers (7 healthy controls, 2 index cases carrying BRCA1 diseasecausing mutation c.421-1GϾA, and 1 index case carrying BRCA1 disease-causing mutation p.L974X). Total RNA was extracted from peripheral blood lymphocytes in a MagNA Pure Compact workstation. MagNA Pure Compact RNA Isolation Kits were used according to the manufacturer's protocol. First-strand cDNA was synthesized with random hexamers (Promega) and a mixture of reverse transcriptases from avian myeloblastosis virus and Moloney murine leukemia virus (Promega).
PCR AMPLIFICATION OF BRCA1 SPLICING ISOFORMS
To amplify different BRCA1 splicing isoforms, we designed primers with the following sequences (5Ј to 3Ј): CATCCAAAGTATGGGCTACAGA (exon7fw), TGTC CAACTCTCTAACCTTG (exon8fw), ACATTGAATT GGCTGCTTGTG (exon8-11Afw), GTCTACATTG AATTGGTGTGGGAG (exon8-9fw), CCAGGGATG AAATCAGTTTGGA (exon10fw), GAATCCAAACT GATTTCATCC (exon10rev), TGGCTCCACATGCAA GTTTGT (exon11Brev), CGTCTCTGAAGACTGC TCA (exon12fw), CTGAGAGGATAGCCCTGAGCA (exon12rev), and TGGAAGGGTAGCTGTTAGAAGG (exon13rev). All primers were designed with the open source software, Primer3 (20 ) . Reverse primers were labeled with 6-carboxyfluorescein (FAM). PCRs were performed with FastStart Taq DNA polymerase (Roche Diagnostics). PCR was conducted under the following cycling conditions, irrespective of the primers used: denaturation at 94°C for 4 min; 25 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and extension at 72°C for 10 min. The number of PCR cycles was kept low to approach linearity of the relative probe signal with the target sequence. The reaction volume was 25 L in all cases.
CAPILLARY ELECTROPHORESIS
Two microliters of the amplification product was diluted to 15L with formamide (Applied Biosystems), and 0.2 L of 500 LIZ fluorescent size standard (Applied Biosystems) was added to each sample. The mixture was denatured at 95°C for 2 min and cooled to 4°C. Amplified PCR products were separated with an ABI 3130 Genetic Analyzer (Applied Biosystems) with polymer POP-7 (Applied Biosystems). Size calling was performed with Genotyper software v4.0 (Applied Biosystems). The same software was used to quantify peak areas. The BRCA1 ⌬9 normalized signal ratio was calculated as the (⌬9 peak area)/(⌬9 peak area ϩ fulllength isoform peak area), as measured after PCR amplification with primers exon8fw and exon10rev. Similarly, the BRCA1 ⌬(9,10) normalized signal ratio was calculated as [⌬(9,10) peak area]/[⌬(9,10) peak area ϩ full-length isoform peak area], as measured after PCR amplification with primers exon7fw and exon11Brev. Finally, the BRCA1 ⌬(9,10,11B) normalized signal ratio was calculated as [⌬(9,10,11B) peak area]/[⌬(9,10,11B) peak area ϩ ⌬11B peak area], as measured after PCR amplification with primers exon8fw and exon12rev. Normalized signal ratios were assessed in triplicate in all samples. Mean normalized signal ratios were compared with the Student t-test. Statistical analysis was carried out with the aid of MedCalc software (MedCalc Software).
SEQUENCING
Samples were sequenced with the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer's protocol.
Results
To date, we have performed BRCA1 mutation scanning in a cohort of 685 index cases of B(O)C families from Spain. The BRCA1 c.591CϾT variant was identified in 10 index cases (1.5%). In addition, we have detected the variant in 4 of 450 healthy controls (0.9%) and in 1 of 326 (0.3%) cases of sporadic breast cancer.
BRCA1 alleles are described almost completely by 10 canonical haplotypes defined by 14 tagging SNPs (17 ); however, haplotypes 1 and 2 are the commonest BRCA1 haplotypes (at least in Western populations), accounting for roughly 78% of all chromosomes (17 ) . In our cohort, the c.591CϾT variant was associated only with haplotype 1 (data not shown); however, most haplotype 1 alleles do not contain this variant. Interestingly, the disease-causing mutation c.5123CϾA was detected only in index cases carrying the c.591CϾT variant. Segregation analysis confirmed that c.5123CϾA was linked to c.591CϾT, at least in our population.
The c.591CϾT variant is located at position Ϫ3 of the intron 9 donor splice site. We used 4 splice siteanalysis tools to predict the effect on splicing, with conflicting results (Table 1 ). The donor splice site scoring was either decreased (MaxEnt scoring and NG2) or preserved (HSF matrices and BDGP). In addition, the c.591CϾT variant was predicted to affect potential splicing regulatory sequences located at the 3Ј end of exon 9. Interestingly, HSF predicted both the disruption of splicing enhancers and the creation of splicing silencers (Table 2) . RESCUE-ESE, PESE, EIE, and ESE-HSF matrices found no differences between variant and wild-type sequences (data not shown).
To investigate a possible effect of the c.591CϾT variant on splicing, we analyzed cDNA samples derived from 7 carriers and 10 noncarriers. After cDNA amplification with primers exon8fw and exon10rev, we observed the expected 201-bp product corresponding to the full-length BRCA1 transcript in all tested samples. An additional product of 155 bp was observed only in c.591CϾT carriers (Fig. 1A) . Because BRCA1 exon 9 spans 46 nucleotides, the data were compatible with exon 9 skipping. The BRCA1 ⌬9 signal was consistently lower than the full-length signal in all carriers (Fig. 1A) . The mean (SD) normalized signal ratio was 0.22 (0.05). Exon 9 skipping was confirmed by direct sequencing (Fig. 1B) . To assess any contribution of the variant allele to the population of full-length transcripts, we sequenced PCR products obtained with a forward primer designed to anneal across the exon 8 -exon 9 junction (exon8-9fw). The chromatogram showed that fulllength transcripts arise predominantly, but not exclusively, from the wild-type allele (Fig. 1C) . The data suggest that the c.591CϾT variant decreases the efficiency of, but does not abolish, the intron 9 donor splice site. BRCA1 splicing variants ⌬(9,10) and ⌬(9,10,11B) do not require a functional intron 9 donor site for proper splicing, at least in theory; however, we were interested in investigating any effect of the c.591CϾT variant on these isoforms and so conducted additional experiments.
After cDNA amplification with the primers exon7fw and exon11Brev, we observed double peaks of 446/449 bp and 323/326 bp that corresponded to fulllength and ⌬(9,10) isoforms, respectively, in all investigated samples (Fig. 2) . In c.591CϾT carriers, we also observed an extra double peak of 400/403 bp (compatible with exon 9 skipping) (Fig. 2) . Sequencing (data not shown) confirmed that the double peaks corresponded to wobble splicing occurring at the 5Ј end of BRCA1 exon 8 (15 ) .
cDNA amplification with primers exon8fw and exon12rev generated 2 PCR products of 396 bp and 273 bp, corresponding to the ⌬11B and ⌬(9,10,11B) isoforms, respectively (Fig. 2) . The products corresponding to the full-length and ⌬(9,10) isoforms were too large to be amplified under the same conditions. An extra product of 350 bp was generated only in c.591CϾT carriers, indicating that exon 9 skipping also occurs in the ⌬11B isoform (Fig. 2) .
Interestingly, the mean normalized signal ratios of the ⌬(9,10) and ⌬(9,10,11B) isoforms were higher in c.591CϾT carriers. These findings were statistically significant (Fig. 2) . The data suggested that c.591CϾT modifies the relative expression level of ⌬(9,10), ⌬(9,10,11B), ⌬11B, and full-length isoforms.
To demonstrate ASS associated with the variant allele, we selected 4 samples (2 c.591CϾT carriers and 2 noncarrier healthy controls) heterozygous for BRCA1 haplotypes 1 and 2 and amplified cDNAs with 3 different forward primers (exon12fw; exon8-11Afw, a primer designed to anneal across the exon 8 -exon 11A junction; and exon10fw) in combination with 1 reverse primer (exon13rev). Use of primers exon8-11Afw and exon10fw individually in combination with primer exon13rev amplified products specific for ⌬(9,10,11B) and ⌬(11B), respectively. All PCR products were sequenced with primer exon12fw. We used the BRCA1 tagging SNP rs1060915 located in exon 13 (c.4308TϾC) to distinguish the expression of T (haplotype 1) and C (haplotype 2) alleles. Sequencing of the PCR fragment encompassing exons 12 and 13 indicated similar expression of the 2 alleles, irrespective of c.591CϾT status (Fig. 3) . With the exception of BRCA1-IRIS (21 ), both exon 12 and exon 13 are present in all BRCA1 isoforms that have been described so far (15 ) . Therefore, the data indicated that the expression levels of wild-type and variant alleles were roughly equivalent. As expected, sequencing of ⌬(9,10,11B) and ⌬11B isoforms showed similar contributions from the 2 alleles in healthy control samples (Fig. 3) . In c.591CϾT carriers, sequencing of ⌬(9,10,11B) products revealed a predominant contribution of the variant (haplotype 1) allele (Fig. 3) . On the contrary, sequencing of ⌬11B products revealed a predominant contribution of the wild-type (haplotype 2) allele (Fig. 3) . Taken together, the data indicated that the population of messengers arising from the variant allele was characterized by a substantial reduction of full-length and ⌬11B isoforms that was compensated by an increase in the population of ⌬(9,10) and ⌬(9,10,11B) isoforms, demonstrating ASS.
Discussion
In this study, we have shown that the BRCA1 c.591CϾT variant is associated with ASS. Several groups have considered that this variant is most likely a neutral polymorphism (22) (23) (24) . The variant is recorded 31 times in the BIC database (Cys197Cys according to the BIC traditional nomenclature) as a silent change of no clinical importance (2 ). Our study further supports a nonpathogenic role for this change. First, the variant is present in 0.9% of the healthy control population. Second, the expression levels of variant and wild-type alleles are similar. Lastly, c.5123CϾA, a known BRCA1 disease-causing mutation (25 ) , is observed in cis with c.591CϾT in B(O)C families. To our knowledge, this report is the first of nonpathogenic ASS occurring in the BRCA1 gene. The ASS is characterized by a reduced population of full-length and ⌬11B transcripts, which is counterbalanced by an increased population of ⌬(9,10) and ⌬(9,10,11B) transcripts such that the overall expression level is similar to that of the wild-type allele. In addition, ASS is characterized by the presence of transcripts lacking exon 9. A schematic representation of c.591CϾT-associated ASS is shown in Fig. 4 .
RNA-splicing analysis is essential for the assessment of many BRCA1 UVs (8, 12, 19, 26, 27 ) . In most cases, analysis is performed by amplifying cDNA with primers flanking the exon likely to be affected by the variant. This approach is designed to detect singlecassette exon events. Interestingly, it will produce misleading results if it is used to test the effect of the BRCA1 c.591CϾT variant on splicing. This is the case because cDNA amplification with primers located in exons 8 -10 (flanking exons) restricts the analysis to the fulllength isoform, thus detecting exon 9 skipping (a frameshift alteration) but missing an increase in the skipping of exons 9 -10 (a naturally occurring BRCA1 isoform preserving the open reading frame). The latter probably explains why the BRCA1 c.591CϾT variant does not have a pathogenic effect [to be more precise, it does not cause an autosomal dominant HB(O)C syndrome], although a role as an allele with a lowpenetrance risk cannot be fully discarded. Moreover, it is important to point out that ASS has been characterized in blood cells and does not necessarily reflect the situation in other tissues, such as the mammary and ovary epithelia.
Our study was not intended to investigate the molecular mechanisms responsible for the association between c.591CϾT and ASS, so we can only speculate. In our opinion, the mere localization of the variant points to a reduced efficiency of the intron 9 splicing donor site as a likely causative mechanism, but other mechanisms are possible. For instance, the variant may target some splicing regulatory sequences. Both hypotheses find some support from in silico analysis (Tables 1 and  2 ). Regardless of the true mechanisms involved, we propose that inclusion/skipping of exons 9 -10 are competing splicing reactions, so that hampering one of the reactions shifts the process to the alternative reaction. In this scenario, a sequence change slightly disrupting any splicing site (or splicing regulatory) sequence is more likely to affect the outcome of the splicing reaction.
At least 33 different BRCA1 variants recorded in the BIC database (2 ) are located in the genomic region encompassing exons 9 and 10. Of these variants, only 4 are considered disease-causing mutations: 3 exonic variants that have been reported only once (c.625_626ins20, c.668_669insA, c.668-669delA) and 1 intronic variant reported 11 times (c.594-2AϾC). The pathogenic nature of the latter is supported by experimental data demonstrating exon 10 skipping (12 ); however, we suggest that the relevant outcome of intron 9 acceptor site deficiency could be (as is the case for intron 9 donor site deficiency) an increased population of ⌬(9,10) transcripts, a possibility that has not yet been investigated.
Our study highlights the fact that splice variants other than the full-length isoform should be considered when analyzing the effect of certain BRCA1 variants (or variants in any other tumor suppressor gene) on splicing. This consideration is important because restricting the in vitro analysis to single-cassette events (namely, select primers for splicing analysis in flanking exons) may introduce bias that affects the interpretation of biological relevance. In addition, our study suggests that the false-negative rate of splicing-prediction programs may increase if alternative splicing variants (naturally occurring alternative splicing pathways) do exist. 
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